This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under FDA review. Shares of Biocon Ltd ended at ₹333.10, up by ₹8.45, or 2.60%, on the BSE.
This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under FDA review. Shares of Biocon Ltd ended at ₹333.10, up by ₹8.45, or 2.60%, on the BSE.